Furfaro et al., in their study using primary BRAF-mutated melanoma cells obtained from patients, demonstrated that either the silencing or pharmacological inhibition of HO-1, in combination with a BRAF inhibitor, resulted in a further reduction in cell viability compared to the effect of a drug administered alone [17]. The gene discussed is BRAF; the disease is melanoma.